BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barazani Y, Hiatt JR, Tong MJ, Busuttil RW. Chronic viral hepatitis and hepatocellular carcinoma. World J Surg 2007;31:1243-8. [PMID: 17440771 DOI: 10.1007/s00268-007-9041-3] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Eriguchi T, Takeda A, Sanuki N, Oku Y, Aoki Y, Shigematsu N, Kunieda E. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system. Int J Radiat Oncol Biol Phys. 2013;85:1006-1011. [PMID: 23102838 DOI: 10.1016/j.ijrobp.2012.09.012] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.0] [Reference Citation Analysis]
2 Moore MS, Ivanina E, Bornschlegel K, Qiao B, Schymura MJ, Laraque F. Hepatocellular Carcinoma and Viral Hepatitis in New York City. Clin Infect Dis 2016;63:1577-83. [PMID: 27585801 DOI: 10.1093/cid/ciw605] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
3 Walter SR, Thein HH, Gidding HF, Amin J, Law MG, George J, Dore GJ. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. J Gastroenterol Hepatol 2011;26:1757-64. [PMID: 21615789 DOI: 10.1111/j.1440-1746.2011.06785.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
4 Shi B, Zhu H, Liu Y, Lü L, Jin C, Ran L, Zhou K, Yang W, Wang Z, Mei Z. Experimental Studies and Clinical Experiences on Treatment of Secondary Hypersplenism with Extracorporeal High-Intensity Focused Ultrasound. Ultrasound in Medicine & Biology 2012;38:1911-7. [DOI: 10.1016/j.ultrasmedbio.2012.07.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
5 Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. Inhibition of HCV 3a core gene through Silymarin and its fractions. Virol J. 2011;8:153. [PMID: 21453551 DOI: 10.1186/1743-422x-8-153] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
6 Gao S, Yang WS, Bray F, Va P, Zhang W, Gao J, Xiang YB. Declining rates of hepatocellular carcinoma in urban Shanghai: incidence trends in 1976-2005. Eur J Epidemiol 2012;27:39-46. [PMID: 22160277 DOI: 10.1007/s10654-011-9636-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
7 Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91. [PMID: 19224838 DOI: 10.1200/JCO.2008.20.7753] [Cited by in Crossref: 1121] [Cited by in F6Publishing: 613] [Article Influence: 86.2] [Reference Citation Analysis]
8 Zhu M, Hong D, Bao Y, Wang C, Pan W. Oridonin induces the apoptosis of metastatic hepatocellular carcinoma cells via a mitochondrial pathway. Oncol Lett 2013;6:1502-6. [PMID: 24179549 DOI: 10.3892/ol.2013.1541] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
9 Govindarajan R, Siegel E, Makhoul I, Williamson S. Bevacizumab and Erlotinib in Previously Untreated Inoperable and Metastatic Hepatocellular Carcinoma. Am J Clin Oncol. 2012; May 24. [Epub ahead of print]. [PMID: 22643560 DOI: 10.1097/COC.0b013e318248d83f] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
10 McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis. 2010;14:461-476. [PMID: 20638025 DOI: 10.1016/j.cld.2010.05.009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
11 Dong Y, Wang A. Aberrant DNA methylation in hepatocellular carcinoma tumor suppression (Review). Oncol Lett 2014;8:963-8. [PMID: 25120642 DOI: 10.3892/ol.2014.2301] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
12 Vidalino L, Doria A, Quarta SM, Crescenzi M, Ruvoletto M, Frezzato F, Trentin L, Turato C, Parolin MC, Ghirardello A, Iaccarino L, Cavalletto L, Chemello L, Gatta A, Pontisso P. SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection. Exp Biol Med (Maywood) 2012;237:793-802. [PMID: 22829702 DOI: 10.1258/ebm.2012.012024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
13 Cheng S, Li E, Lok AS. Predictors and Barriers to Hepatitis B Screening in a Midwest Suburban Asian Population. J Community Health 2017;42:533-43. [PMID: 27770375 DOI: 10.1007/s10900-016-0285-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
14 Milionis C. Serological markers of Hepatitis B and C among juvenile immigrants from Albania settled in Greece. Eur J Gen Pract. 2010;16:236-240. [PMID: 20954813 DOI: 10.3109/13814788.2010.525631] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
15 Moore KJ, Gauri A, Koru-Sengul T. Prevalence and sociodemographic disparities of Hepatitis C in Baby Boomers and the US adult population. J Infect Public Health. 2019;12:32-36. [PMID: 30170837 DOI: 10.1016/j.jiph.2018.08.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
16 Nguyen VT, Amin J, Law MG, Dore GJ. Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales, Australia. J Gastroenterol Hepatol. 2009;24:436-442. [PMID: 19175834 DOI: 10.1111/j.1440-1746.2008.05577.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
17 Ashfaq UA, Masoud MS, Khaliq S, Nawaz Z, Riazuddin S. Inhibition of hepatitis C virus 3a genotype entry through Glanthus Nivalis Agglutinin. Virol J 2011;8:248. [PMID: 21599979 DOI: 10.1186/1743-422X-8-248] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
18 Post SE, Sodhi NK, Peng CH, Wan K, Pollack HJ. A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective. Health Aff (Millwood) 2011;30:340-8. [PMID: 21289356 DOI: 10.1377/hlthaff.2008.0905] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
19 Wang MX, Chen D, Zhao YY, Yang B, Jiang JP, Zeng FJ, Wei L, Chen ZS. Role of selected criteria and preventive chemotherapy in tumor recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2020;19:378-83. [PMID: 32622825 DOI: 10.1016/j.hbpd.2020.06.008] [Reference Citation Analysis]
20 Jeong KY, Lee EJ, Yang SH, Seong J. Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma. J Radiat Res 2015;56:37-45. [PMID: 25225286 DOI: 10.1093/jrr/rru077] [Reference Citation Analysis]
21 Pančoška P, Skála L, Nešetřil J, Carr BI. Evaluation of total hepatocellular cancer lifespan, including both clinically evident and preclinical development, using combined network phenotyping strategy and fisher information analysis. Semin Oncol 2015;42:339-46. [PMID: 25843738 DOI: 10.1053/j.seminoncol.2014.12.025] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Fassina A. 'The map is not the territory': FNA the map and liver the territory. Cytopathology 2011;22:285-6. [PMID: 21923726 DOI: 10.1111/j.1365-2303.2011.00928.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Gonsalves CF, Brown DB. Chemoembolization of hepatic malignancy. Abdom Imaging. 2009;34:557-565. [PMID: 18668189 DOI: 10.1007/s00261-008-9446-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
24 Xia VW, Taniguchi M, Steadman RH. The changing face of patients presenting for liver transplantation. Curr Opin Organ Transplant. 2008;13:280-284. [PMID: 18685318 DOI: 10.1097/mot.0b013e328300a070] [Cited by in Crossref: 60] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
25 Kim KE, Park M, Bentley-hibbert S, Baek S, Kim YC, Kim M, Kim KW, Auh YH. Hepatocellular carcinoma: clinical and radiological findings in patients with chronic B viral hepatitis and chronic C viral hepatitis. Abdom Imaging 2012;37:591-4. [DOI: 10.1007/s00261-011-9799-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
26 Kawamura E, Enomoto M, Kotani K, Hagihara A, Fujii H, Kobayashi S, Iwai S, Morikawa H, Kawabe J, Tominaga K. Effect of mosapride citrate on gastric emptying in interferon-induced gastroparesis. Dig Dis Sci. 2012;57:1510-1516. [PMID: 22399248 DOI: 10.1007/s10620-012-2085-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
27 Kwong SL, Stewart SL, Aoki CA, Chen MS Jr. Disparities in hepatocellular carcinoma survival among Californians of Asian ancestry, 1988 to 2007. Cancer Epidemiol Biomarkers Prev. 2010;19:2747-2757. [PMID: 20823106 DOI: 10.1158/1055-9965.epi-10-0477] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
28 Kim T, Hori M, Onishi H. Liver Masses With Central or Eccentric Scar. Seminars in Ultrasound, CT and MRI 2009;30:418-25. [DOI: 10.1053/j.sult.2009.07.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
29 Torres-poveda K, Burguete-garcía AI, Madrid-marina V. Liver cirrhosis and hepatocellular carcinoma in Mexico: impact of chronic infection by hepatitis viruses B and C. Annals of Hepatology 2011;10:556-8. [DOI: 10.1016/s1665-2681(19)31525-x] [Cited by in Crossref: 9] [Article Influence: 0.8] [Reference Citation Analysis]
30 Dunst D, Ream JM, Khalef V, Hajdu CH, Rosenkrantz AB. Comparison of MRI features of pathologically proven hepatocellular carcinoma between patients with hepatitis B and hepatitis C infection. Clin Imaging 2016;40:352-6. [PMID: 27133666 DOI: 10.1016/j.clinimag.2016.01.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009;16:453-463. [PMID: 19302335 DOI: 10.1111/j.1365-2893.2009.01117.x] [Cited by in Crossref: 185] [Cited by in F6Publishing: 198] [Article Influence: 14.2] [Reference Citation Analysis]
32 Gheorghe DN, Foia L, Toma V, Surdu A, Herascu E, Popescu DM, Surlin P, Vere CC, Rogoveanu I. Hepatitis C Infection and Periodontal Disease: Is there a Common Immunological Link? J Immunol Res 2018;2018:8720101. [PMID: 29725605 DOI: 10.1155/2018/8720101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
33 Iizuka Y, Matsuo Y, Ishihara Y, Akimoto M, Tanabe H, Takayama K, Ueki N, Yokota K, Mizowaki T, Kokubo M, Hiraoka M. Dynamic tumor-tracking radiotherapy with real-time monitoring for liver tumors using a gimbal mounted linac. Radiother Oncol 2015;117:496-500. [PMID: 26362722 DOI: 10.1016/j.radonc.2015.08.033] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
34 Yang Y, Zheng B, Han Q, Zhang C, Tian Z, Zhang J. Targeting blockage of STAT3 inhibits hepatitis B virus-related hepatocellular carcinoma. Cancer Biol Ther. 2016;17:449-456. [PMID: 26934469 DOI: 10.1080/15384047.2016.1156257] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
35 Tong MJ, Sun HE, Hsien C, Lu DS. Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic. Dig Dis Sci. 2010;55:826-835. [PMID: 19960258 DOI: 10.1007/s10620-009-1059-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
36 Huang CC, Chen HY, Chang RH, Liao PA, Lien HH, Hung CS, Yang SS, Hu JT. A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007-2015. Drug Des Devel Ther 2019;13:397-404. [PMID: 30774305 DOI: 10.2147/DDDT.S191334] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
37 Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J. Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma. JCO 2009;27:843-50. [DOI: 10.1200/jco.2008.18.3301] [Cited by in Crossref: 238] [Cited by in F6Publishing: 103] [Article Influence: 18.3] [Reference Citation Analysis]
38 Yen CJ, Lin YJ, Yen CS, Tsai HW, Tsai TF, Chang KY, Huang WC, Lin PW, Chiang CW, Chang TT. Hepatitis B virus X protein upregulates mTOR signaling through IKKβ to increase cell proliferation and VEGF production in hepatocellular carcinoma. PLoS One. 2012;7:e41931. [PMID: 22848663 DOI: 10.1371/journal.pone.0041931] [Cited by in Crossref: 37] [Cited by in F6Publishing: 46] [Article Influence: 3.7] [Reference Citation Analysis]
39 Gnoni A, Santini D, Scartozzi M, Russo A, Licchetta A, Palmieri V, Lupo L, Faloppi L, Palasciano G, Memeo V. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? Expert Opin Ther Targets. 2015;19:1623-1635. [PMID: 26212068 DOI: 10.1517/14728222.2015.1071354] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
40 Al-Naamani K, Al-Hashami Z, Al-Siyabi O, Al-Moundri M, Al-Bahrani B, Al-Sinani S, Al-Zakwani I, Omar H, Al-Busafi SA, Al-Zuhaibi H, AlMamari A, Kamath BR, Al-Kalbani A, Burney IA. Hepatocellular Carcinoma in Oman: An analysis of 284 cases. Sultan Qaboos Univ Med J 2020;20:e316-22. [PMID: 33110647 DOI: 10.18295/squmj.2020.20.03.011] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Pircher A, Medinger M, Drevs J. Liver cancer: Targeted future options. World J Hepatol 2011; 3(2): 38-44 [PMID: 21423913 DOI: 10.4254/wjh.v3.i2.38] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
42 Tanase AM, Dumitrascu T, Dima S, Grigorie R, Marchio A, Pineau P, Popescu I. Influence of hepatitis viruses on clinicopathological profiles and long-term outcome in patients undergoing surgery for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2014;13:162-72. [PMID: 24686543 DOI: 10.1016/s1499-3872(14)60026-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
43 Eriguchi T, Takeda A, Tateishi Y, Tsurugai Y, Sanuki N, Ebinuma H, Horita N. Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and meta-analysis of propensity score studies. Hepatol Res 2021;51:813-22. [PMID: 33856722 DOI: 10.1111/hepr.13647] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Ji SP, Li Q, Dong H. Therapy and prognostic features of primary clear cell carcinoma of the liver. World J Gastroenterol 2010; 16(6): 764-769 [PMID: 20135727 DOI: 10.3748/wjg.v16.i6.764] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
45 Ng J, Wu J. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon 2012;12:e7635. [PMID: 23233865 DOI: 10.5812/hepatmon.7635] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
46 Eriguchi T, Tsukamoto N, Kuroiwa N, Nemoto T, Ogata T, Okubo Y, Nakano S, Sugawara A. Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. Pract Radiat Oncol 2021;11:44-52. [PMID: 32791232 DOI: 10.1016/j.prro.2020.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, Yersiz H, Lu DS, Lassman C, Tong MJ, Hiatt JR, Busuttil RW. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246:502-509; discussion 509. [PMID: 17717454 DOI: 10.1097/sla.0b013e318148c704] [Cited by in Crossref: 331] [Cited by in F6Publishing: 103] [Article Influence: 22.1] [Reference Citation Analysis]
48 Masiuk M. Nucleolin – Characteristics of Protein and its Role in Biology of Cancers and Viral Infections. Advances in Cell Biology 2008;-1:1-19. [DOI: 10.2478/v10052-008-0003-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
49 Jeong KY, Lee EJ, Kim SJ, Yang SH, Sung YC, Seong J. Irradiation-induced localization of IL-12-expressing mesenchymal stem cells to enhance the curative effect in murine metastatic hepatoma. Int J Cancer 2015;137:721-30. [PMID: 25639194 DOI: 10.1002/ijc.29428] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
50 Sarpel U, Ayo D, Lobach I, Xu R, Newman E. Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma. HPB (Oxford). 2012;14:741-745. [PMID: 23043662 DOI: 10.1111/j.1477-2574.2012.00507.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
51 Yen CJ, Lin YJ, Yen CS, Tsai HW, Tsai TF, Chang KY, Huang WC, Lin PW, Chiang CW, Chang TT. Hepatitis B virus X protein upregulates mTOR signaling through IKKβ to increase cell proliferation and VEGF production in hepatocellular carcinoma. PLoS One. 2012;7:e41931. [PMID: 22848663 DOI: 10.1371/journal.pone.0041931.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Thitinan S, McConville JT. Interferon alpha delivery systems for the treatment of hepatitis C. Int J Pharm 2009;369:121-35. [PMID: 19103271 DOI: 10.1016/j.ijpharm.2008.11.027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
53 Carr BI, Guerra V, Steel JL, Lu SN. A comparison of patients with hepatitis B- or hepatitis C-based advanced-stage hepatocellular carcinoma. Semin Oncol. 2015;42:309-315. [PMID: 25843735 DOI: 10.1053/j.seminoncol.2014.12.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
54 Kara B, Doran F, Kara IO, Akkiz H, Sandikci M. Expression of c-kit protooncogen in hepatitis B virus-induced chronic hepatitis, cirrhosis and hepatocellular carcinoma: has it a diagnostic role?: Expression of c-kit in hepatitis B virus induced hepatocellular carcinoma. International Journal of Clinical Practice 2008;62:1206-11. [DOI: 10.1111/j.1742-1241.2007.01675.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
55 Zhou L, Rui JA, Wang SB, Chen SG, Qu Q. LCSGJ-T classification, 6th or 5th edition TNM staging did not independently predict the long-term prognosis of HBV-related hepatocellular carcinoma after radical hepatectomy. J Surg Res 2010;159:538-44. [PMID: 19111323 DOI: 10.1016/j.jss.2008.09.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
56 Naik PR, Kumar P, Kumar PV. Primary pleomorphic liposarcoma of liver: a case report and review of the literature.Case Reports Hepatol. 2013;2013:398910. [PMID: 25374715 DOI: 10.1155/2013/398910] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
57 Yang H, Chen K, Wei Y, Liu F, Li H, Zhou Z, Li B. Treatment of spontaneous ruptured hepatocellular carcinoma: A single-center study. Pak J Med Sci 2014;30:472-6. [PMID: 24948961 DOI: 10.12669/pjms.303.4001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 0.1] [Reference Citation Analysis]
58 Izzo F, Piccirillo M, Albino V, Palaia R, Belli A, Granata V, Setola S, Fusco R, Petrillo A, Orlando R, Tosone G, Scordino F, Curley SA. Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients. HPB (Oxford) 2013;15:985-90. [PMID: 23607636 DOI: 10.1111/hpb.12080] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
59 Chirica M, Tranchart H, Tan V, Faron M, Balladur P, Paye F. Infection with hepatitis C virus is an adverse prognostic factor after liver resection for early-stage hepatocellular carcinoma: implications for the management of hepatocellular carcinoma eligible for liver transplantation. Ann Surg Oncol. 2013;20:2405-2412. [PMID: 23338483 DOI: 10.1245/s10434-012-2861-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
60 Ollier L, Laffont C, Kechkekian A, Doglio A, Giordanengo V. Detection of antibodies to hepatitis B core antigen using the Abbott ARCHITECT anti-HBc assay: analysis of borderline reactive sera. J Virol Methods. 2008;154:206-209. [PMID: 18848582 DOI: 10.1016/j.jviromet.2008.09.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
61 Jeong KY, Lee EJ, Yang SH, Seong J. Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma. J Radiat Res 2015;56:37-45. [PMID: 25225286 DOI: 10.1093/jrr/rru077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
62 Pacini L, Graziani R, Bartholomew L, De Francesco R, Paonessa G. Naturally occurring hepatitis C virus subgenomic deletion mutants replicate efficiently in Huh-7 cells and are trans-packaged in vitro to generate infectious defective particles. J Virol 2009;83:9079-93. [PMID: 19587042 DOI: 10.1128/JVI.00308-09] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
63 Deng YR, Yoshida K, Jin QL, Murata M, Yamaguchi T, Tsuneyama K, Moritoki Y, Niu JQ, Matsuzaki K, Lian ZX. Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection. Clin Exp Immunol 2014;176:102-11. [PMID: 24372395 DOI: 10.1111/cei.12259] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
64 Aljumah AA, Kuriry H, Faisal N, Alghamdi H. Clinicopathologic characteristics andoutcomes of hepatocellular carcinoma associated with chronic hepatitis B versus hepatitis C infection. Ann Saudi Med 2018;38:358-65. [PMID: 30284991 DOI: 10.5144/0256-4947.2018.358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
65 Ramirez AG, Weiss NS, Holden AE, Suarez L, Cooper SP, Munoz E, Naylor SL. Incidence and risk factors for hepatocellular carcinoma in Texas Latinos: implications for prevention research. PLoS One. 2012;7:e35573. [PMID: 22530052 DOI: 10.1371/journal.pone.0035573] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
66 Tong MJ, Chavalitdhamrong D, Lu DS, Raman SS, Gomes A, Duffy JP, Hong JC, Busuttil RW. Survival in Asian Americans after treatments for hepatocellular carcinoma: a seven-year experience at UCLA. J Clin Gastroenterol. 2010;44:e63-e70. [PMID: 19745756 DOI: 10.1097/mcg.0b013e3181b4b68b] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
67 Luo Z, Xie Y, Deng M, Zhou X, Ruan B. Prevalence of hepatitis B in the southeast of China: a population-based study with a large sample size. Eur J Gastroenterol Hepatol. 2011;23:695-700. [PMID: 21617533 DOI: 10.1097/meg.0b013e328347322b] [Cited by in Crossref: 45] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
68 Davis GL, Roberts WL. The Healthcare Burden Imposed by Liver Disease in Aging Baby Boomers. Curr Gastroenterol Rep 2010;12:1-6. [DOI: 10.1007/s11894-009-0087-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
69 Robbins AS, Daily MF, Aoki CA, Chen MS Jr, Troppmann C, Perez RV. Decreasing disparity in liver transplantation among white and Asian patients with hepatocellular carcinoma: California, 1998-2005. Cancer. 2008;113:2173-2179. [PMID: 18792066 DOI: 10.1002/cncr.23766] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
70 Shaw JJ, Shah SA. Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean? Expert Rev Gastroenterol Hepatol 2011;5:365-70. [PMID: 21651354 DOI: 10.1586/egh.11.20] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
71 Barry AE, Baldeosingh R, Lamm R, Patel K, Zhang K, Dominguez DA, Kirton KJ, Shah AP, Dang H. Hepatic Stellate Cells and Hepatocarcinogenesis. Front Cell Dev Biol 2020;8:709. [PMID: 32850829 DOI: 10.3389/fcell.2020.00709] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
72 Hwang JP, Hassan MM. Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation. BMC Cancer 2009;9:46. [PMID: 19193234 DOI: 10.1186/1471-2407-9-46] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]